An observational study in Optokinetic Nystagmus, sponsored by Julie Dawson. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-10.
Sponsored by Julie Dawson · Observational
Clinical investigation of a medical device (CAVA) for recording eye movements. Healthy volunteers will wear the device for 23 hours a day, for 30 days. On 8 separate days of the trial they will induce optokinetic nystagmus (a normal reflex in response to full-field motion) by watching a short video of less than 1 minute in duration. The data will be analysed offline by a scientist, who will attempt to identify the dates that the nystagmus was induced.
Dizziness is a common condition that is responsible for a significant degree of material morbidity and burden on the National Health Service. There are multiple causes of dizziness, and these originate from pathologies affecting a large variety of different organ systems. Dizziness is usually episodic and short-lived, so when a patient presents to their health care provider, examination is often normal. As such, diagnosis is challenging and patients often experience significant delay in receiving a diagnosis. The investigators have developed a prototype device for monitoring dizziness and have tested it in a small group of volunteers. The results showed that their device is capable of accurately, precisely and reliably identifying periods of dizziness over a short period of time. Independent market research has confirmed that their device could meet the required clinical need, would be desired by clinicians, and that there is no equivalent solution currently available. The investigators have received an award from the Medical Research Council to trial their device in a large cohort of healthy volunteers. Once completed, they will be positioned well to test their device in a cohort of patients with a defined dizziness syndrome, before further testing their device in a more diverse patient population. Once validated, developed and brought to market, the device would provide early diagnosis and accurate treatment for a significant proportion of the patient population. This would save the National Health Service money by reducing multiple visits to General Practitioner clinics, reducing referrals to multiple specialist clinics, and reducing treatment required from falls and other conditions associated with dizziness.
The overall aim of this trial is to test a fully evolved device for the continuous recording of eye movements over a prolonged period of time. For the purpose of this study, the monitoring period is 23 hours a day, for 30 days. The device is composed of two components: a bespoke single-use sensor array that adheres to the participant's face, and a small reusable module that contains a battery, microcomputer, data storage facility, battery and connection port.
The investigators intend to confirm that the device will be able to capture any occurrence, of a minimum period of thirty seconds, of artificially induced nystagmus, within a 24-hour period of time. Each participant will be provided with the device and enough single-use electrode arrays to allow the array to be changed every 24 hours, for thirty days. Participants will be allowed to remove the sensor array for up to 60 minutes each day to allow them to wash and/or shower. On eight of the thirty days for which they wear the array, each participant will be required to induce physiological nystagmus by viewing optokinetic video footage. The footage will be viewed on a portable screen (of a deactivated mobile phone) inside a Virtual Reality headset. These will be issued to the participants at the beginning of the trial. Participants will undertake the procedure whilst stationary for the first four days, and whilst walking gently on the spot for the remaining four days. The identity of these days will not be revealed to the blinded investigator who will later analyse the data. At the end of the thirty-day trial, the sensitivity and specificity of the device will be determined by assessing whether the data can be used to correctly identify the dates that participants induced nystagmus.
27 studies on the registry are indexed under Nystagmus, Pathologic; 3 are open to participants now.
Browse Nystagmus, Pathologic studies →Julie Dawson is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Healthy volunteers, aged 18 or over.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All trial participants are within this group. All trial participants will wear the CAVA device for up to 23 hours a day, for 30 days.
Device: CAVA
prototype device for monitoring dizziness
Sensitivity and Specificity of a Computer Algorithm to Detect Artificially Induced Nystagmus
Dates containing nystagmus. Of the \~450 days' worth of data captured during the study, 120 will contain artificially induced nystagmus. A computer algorithm has been developed at the University of East Anglia for detecting nystagmus. The key measurements are the sensitivity and specificity of the algorithm's results when applied to data captured during the trial. This measurement will be assessed post-trial.
Time frame: 30 days
Post-trial Participant Questionnaire.
A 2-page questionnaire producing qualitative and quantitative data. Participants rate different aspects of their experiences with the device using a sliding scale and have the opportunity to write more detailed descriptions.
Time frame: 30 days
Compliance With the Device.
1 - There is a minimum of 80% compliance with wearing the device for each single day of the trial for a minimum of 80% of participants. 2 There is a minimum of 80% compliance with wearing the device for the entirety of the 30-day trial for a minimum of 80% of participants.
Time frame: 30 days
Data Usefulness
The device provides less than 5% non-useful data for each participant. We will report the percentage of non-useful data (corrupted or flat-line data) that is captured for each participant.
Time frame: 30 days
Data Usefulness
The device provides less than 5% non-useful data for the entirety of the 30-day trial across all participants. We will report the percentage of non-useful data (corrupted or flat-line data) that is captured over the entire trial, across all participants.
Time frame: 30 days
Event Marker Functioning
During a return visit, the event marker on each device will be pressed and the time noted. Post-trial, the data on the device will be examined to confirm that an event was recorded on the correct date. This will produce either a positive or negative outcome, depending on whether the event marker button press is present in the data or not. The percentage of identifiable button presses across all devices will be reported.
Time frame: 30 days
Time Stamp Accuracy
The difference will be calculated between the time noted by the research team and the time logged by the device when the event marker was activated. The time difference (in hh:mm:ss) will be calculated across all devices and we will report the average and standard deviation of the clock drift.
Time frame: 30 days
Accelerometer Functioning
Participants will perform a number of head movements and the device data will be examined visually to confirm that they can be identified. This will produce either a positive or negative outcome for each head movement, depending on whether the movement is visible in the data or not. The proportion of successfully identified head movements will be reported.
Time frame: 30 days
Accuracy of Nystagmus Beat Direction
Participants will undergo caloric testing at the end of the trial, during which they will wear conventional Videonystagmography (VNG) goggles as well as the CAVA device. The beat direction (whether the fast phase of the nystagmus is towards the left or right ear) will be determined from both sources of data during the period of nystagmus captured. This will produce either a positive or negative outcome, depending on whether the beat direction matches in both data sources. The proportion of matches will be reported.
Time frame: 1 hour
Accuracy of Nystagmus Onset Time
Also from the data captured during caloric testing, the start time of nystagmus will be identified from both the VNG data and data captured by the CAVA device. The time difference (in mm:ss) will be calculated between the two data sources and the mean time difference will be reported.
Time frame: 1 hour
Accuracy of Nystagmus Finishing Time
Also from the data captured during caloric testing, the finishing time of nystagmus will be identified from both the VNG data and data captured by the CAVA device. The time difference (in mm:ss) will be calculated between the two data sources and the mean time difference will be reported.
Time frame: 1 hour
Accuracy of Nystagmus Peak Time
Also from the data captured during caloric testing, the time at which the nystagmus reaches its maximum slow phase velocity will be calculated from the VNG data and the data captured by the CAVA device. The time difference (in mm:ss) will be calculated between the two data sources and the mean time difference will be reported.
Time frame: 1 hour
Accuracy of Nystagmus Frequency
Also from the data captured during caloric testing, the number of beats will be counted during the period identified as the nystagmus peak time. This will be calculated for both the VNG data and the data captured by the CAVA device. From the number of beats and time duration examined, the frequency of the nystagmus will be determined. The difference between the two systems will be calculated and the mean difference will be reported. The Unit of Measure will be Hz (number of beats per second).
Time frame: 1 hour
Data Drop-outs
The device provides less 5 drop-outs for each single day of the trial for each participant. We will report the maximum number of drop-outs (periods when the device stopped logging) per participant, per day.
Time frame: 30 days
Data Drop-outs
The device provides less 60 drop-outs for the entirety of the 30-day trial across all participants. We will report the total number of drop-outs that occurred over the entire trial, across all participants.
Time frame: 30 days
| Milestone | Healthy Volunteers |
|---|---|
| Started | 18 |
| Completed | 10 |
| Not completed | 8 |
Dates containing nystagmus. Of the \~450 days' worth of data captured during the study, 120 will contain artificially induced nystagmus. A computer algorithm has been developed at the University of East Anglia for detecting nystagmus. The key measurements are the sensitivity and specificity of the algorithm's results when applied to data captured during the trial. This measurement will be assessed post-trial.
| Percent | Healthy Volunteers |
|---|---|
| Sensitivity | 99.1 |
| Specificity | 98.6 |
A 2-page questionnaire producing qualitative and quantitative data. Participants rate different aspects of their experiences with the device using a sliding scale and have the opportunity to write more detailed descriptions.
Results for this outcome have not been posted.
1 - There is a minimum of 80% compliance with wearing the device for each single day of the trial for a minimum of 80% of participants. 2 There is a minimum of 80% compliance with wearing the device for the entirety of the 30-day trial for a minimum of 80% of participants.
| percentage of participants | Healthy Volunteers |
|---|---|
| Daily compliance | 82 |
| 30-day compliance | 100 |
The device provides less than 5% non-useful data for each participant. We will report the percentage of non-useful data (corrupted or flat-line data) that is captured for each participant.
| Percentage of non-useful data | Healthy Volunteers |
|---|---|
| Data Usefulness | 0 ± 0 |
The device provides less than 5% non-useful data for the entirety of the 30-day trial across all participants. We will report the percentage of non-useful data (corrupted or flat-line data) that is captured over the entire trial, across all participants.
| percentage of non-useful data | Healthy Volunteers |
|---|---|
| Data Usefulness | 0 |
During a return visit, the event marker on each device will be pressed and the time noted. Post-trial, the data on the device will be examined to confirm that an event was recorded on the correct date. This will produce either a positive or negative outcome, depending on whether the event marker button press is present in the data or not. The percentage of identifiable button presses across all devices will be reported.
| percentage of button presses identified | Healthy Volunteers |
|---|---|
| Event Marker Functioning | 100 |
The difference will be calculated between the time noted by the research team and the time logged by the device when the event marker was activated. The time difference (in hh:mm:ss) will be calculated across all devices and we will report the average and standard deviation of the clock drift.
| minutes per day | Healthy Volunteers |
|---|---|
| Time Stamp Accuracy | -17.49 ± 1.47 |
Participants will perform a number of head movements and the device data will be examined visually to confirm that they can be identified. This will produce either a positive or negative outcome for each head movement, depending on whether the movement is visible in the data or not. The proportion of successfully identified head movements will be reported.
| percentage of movements identified | Healthy Volunteers |
|---|---|
| Slow head turning | 97 |
| Slow head nodding | 100 |
| Slow head tilting | 100 |
| Fast head turning | 93 |
| Fast head nodding | 100 |
| Fast head tilting | 97 |
Participants will undergo caloric testing at the end of the trial, during which they will wear conventional Videonystagmography (VNG) goggles as well as the CAVA device. The beat direction (whether the fast phase of the nystagmus is towards the left or right ear) will be determined from both sources of data during the period of nystagmus captured. This will produce either a positive or negative outcome, depending on whether the beat direction matches in both data sources. The proportion of matches will be reported.
Results for this outcome have not been posted.
Also from the data captured during caloric testing, the start time of nystagmus will be identified from both the VNG data and data captured by the CAVA device. The time difference (in mm:ss) will be calculated between the two data sources and the mean time difference will be reported.
Results for this outcome have not been posted.
Also from the data captured during caloric testing, the finishing time of nystagmus will be identified from both the VNG data and data captured by the CAVA device. The time difference (in mm:ss) will be calculated between the two data sources and the mean time difference will be reported.
Results for this outcome have not been posted.
Also from the data captured during caloric testing, the time at which the nystagmus reaches its maximum slow phase velocity will be calculated from the VNG data and the data captured by the CAVA device. The time difference (in mm:ss) will be calculated between the two data sources and the mean time difference will be reported.
Results for this outcome have not been posted.
Also from the data captured during caloric testing, the number of beats will be counted during the period identified as the nystagmus peak time. This will be calculated for both the VNG data and the data captured by the CAVA device. From the number of beats and time duration examined, the frequency of the nystagmus will be determined. The difference between the two systems will be calculated and the mean difference will be reported. The Unit of Measure will be Hz (number of beats per second).
Results for this outcome have not been posted.
The device provides less 5 drop-outs for each single day of the trial for each participant. We will report the maximum number of drop-outs (periods when the device stopped logging) per participant, per day.
| Number of drop outs | Healthy Volunteers |
|---|---|
| Data Drop-outs | 0.2353 ± 0.4372 |
The device provides less 60 drop-outs for the entirety of the 30-day trial across all participants. We will report the total number of drop-outs that occurred over the entire trial, across all participants.
| Total number of drop outs | Healthy Volunteers |
|---|---|
| Data Drop-outs | 4 |
Collected over 30 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Volunteers | 0/18 (0%) | 0/18 (0%) | 10/18 (55.6%) |
| Event | Healthy Volunteers |
|---|---|
| Redness under electrodesSkin and subcutaneous tissue disorders | 8/18 |
| Over rubbed under left eyeSkin and subcutaneous tissue disorders | 1/18 |
| Erosion under all electrode sitesSkin and subcutaneous tissue disorders | 1/18 |
| Disturbed sleepProduct Issues | 1/18 |
| Sore throatRespiratory, thoracic and mediastinal disorders | 1/18 |
| Allergic reactionSkin and subcutaneous tissue disorders | 1/18 |
| Swollen lymph nodesRespiratory, thoracic and mediastinal disorders | 1/18 |
| Age, Categorical(Participants) | Healthy Volunteers |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 18 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Healthy Volunteers |
|---|---|
| Female | 12 |
| Male | 6 |
| Race and Ethnicity Not Collected(Participants) | Healthy Volunteers |
|---|
| Healthy Volunteers(Participants) | Healthy Volunteers |
|---|---|
| Count of participants | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Julie Dawson